Navigation Links
Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
Date:3/19/2013

erially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and products liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amgen Announces 2013 Second Quarter Dividend
2. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
5. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
7. Amgen Announces 2012 Third Quarter Dividend
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen to Acquire Micromet
10. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
11. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... speciality,pharmaceutical company focused on the discovery and development ... problem of microbial,resistance, announces today the appointment of ... (SAB). Novexel,s SAB is chaired by Dr.,David Shlaes ... who is currently,Adjunct Professor at the Department of ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... company serving the,pharmaceutical, biotechnology, and medical device industries, ... announced its financial results for,fourth-quarter and full-year 2008. ... ), Highlights, ...
... March 25 David Koos, Chairman and CEO of ... BMSN), told the editors of The Wall Street Transcript, ... is an excellent possibility that the company "would have ... alliances and contracts "with companies engaged either in cryogenic ...
Cached Biology Technology:Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 2Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 20Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That 'Positive Cash Flow' Is Possible in '09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview 2
(Date:4/17/2014)... RSV infection , Respiratory syncytial virus (RSV) ... infections, generating life-threating illness in very young and ... limited. RSV enters host cells through the fusion ... bundle. Small interfering peptides that prevent bundle formation ... are highly susceptible to degradation. In this issue ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... apparent paradox exists: Despite choosing a career working with ... from mild disgust to extreme arachnophobia. ... Entomologist features the results of a survey involving ... fear of spiders. Although most entomologists had low scores ...
... producing the building blocks of life, amino acids, in research ... The team from Imperial College London, the University of ... icy comets collide into a planet, amino acids can be ... rocky meteorite crashes into a planet with an icy surface. ...
... has a simple message for fellow hypertension researchers: think ... percent of adults have high blood pressure and 50-75 ... powerful endothelin system, which helps the body eliminate salt, ... research and clinical world focus on suppressing a better-known ...
Cached Biology News:Arachnophobic entomologists: When 2 more legs make a big difference 2Scientists discover cosmic factory for making building blocks of life 2Hypertension researcher encourages colleagues to expand their focus 2Hypertension researcher encourages colleagues to expand their focus 3
... TempliPhi 100 Amplification Kit, 100 reactions. ... sequencing in 4-6 h.Generate microgram quantities ... of starting material.Use amplified DNA directly ... from bacterial or M13 liquid cultures, ...
... Microplate Rack inserts fit ... Rack, and allow you to ... capacity, shake deepwell format plates ... many plates from the shaker ...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Spaced cover glasses to promote effective hybridization...
Biology Products: